Obesity / Overweight | Unmet Need | US/EU | 2023

Obesity is a significant public health concern in the United States and Europe. Its chronic progression is associated with type 2 diabetes and adverse cardiovascular (CV) health. Since 2012, several novel branded drugs have entered the market with varying degrees of commercial success. Approved agents include Novo Nordisk’s Wegovy (semaglutide) and Saxenda (liraglutide), Vivus’s Qsymia (phentermine / topiramate), and Nalpropion Pharmaceuticals’ Contrave (naltrexone / bupropion). In this report, endocrinologists compare current antiobesity drugs and discuss the attributes that the next generation of drugs should have to serve this medically important population and to succeed commercially in a potentially lucrative market.

QUESTIONS ANSWERED

How do endocrinologists rate current antiobesity drugs, such as Novo Nordisk’s Wegovy and Saxenda?
What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
What trade-offs across different clinical attributes and prices are needed from new obesity drugs to be preferred by endocrinologists?
How can less-frequent dosing, route of administration, cardiovascular and renal benefit, and efficacy influence physician preference? Discover the answers with Clarivate’s fully customizable Target Product Profile (TPP) simulator.

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 31 European endocrinologists fielded in March 2023

Key companies: Novo Nordisk, Vivus, Currax Pharmaceuticals, Orexigen Therapeutics

Key drugs: Wegovy, Saxenda, Qsymia, Contrave/Mysimba, Xenical, phentermine

Contact sales account_box

Unmet Need US 2023

Report

Type 1 Diabetes – Current Treatment – Treatment Algorithms: Claims Data Analysis – Type 1 Diabetes (US)

Intensive insulin regimens have proven effective in delaying the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Thus, insulin remains the…

north_east

Report

Postpartum Depression – Current Treatment – Treatment Algorithms: Claims Data Analysis – Postpartum Depression (US)

Postpartum depression (PPD) refers to depression experienced by women after childbirth. The PPD drug market consists of very limited treatment options specifically approved for PPD, so drugs used…

north_east

Report

Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)

Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the vein affected. Current…

north_east

Report

Uterine Fibroids – Current Treatment – Treatment Algorithms: Claims Data Analysis – Uterine Fibroids (US)

Treatment for uterine fibroids includes pharmacological approaches and surgical procedures. NSAIDs help alleviate the pain but do not reduce the fibroids’ size. Progestins (e.g., norethindrone,…

north_east

Report

Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – IBS-Constipation (Including IBS Without Diarrhea) (US)

Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is classified into three subtypes:…

north_east

Product logins

Obesity / Overweight | Unmet Need | US/EU | 2023

Related Market Assessment Reports

Type 1 Diabetes – Current Treatment – Treatment Algorithms: Claims Data Analysis – Type 1 Diabetes (US)

Postpartum Depression – Current Treatment – Treatment Algorithms: Claims Data Analysis – Postpartum Depression (US)

Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)

Uterine Fibroids – Current Treatment – Treatment Algorithms: Claims Data Analysis – Uterine Fibroids (US)

Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – IBS-Constipation (Including IBS Without Diarrhea) (US)

Follow us

Contact us